Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis
Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-06-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186605098172416 |
|---|---|
| author | K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. V. Davydovskaya M. N. Zakharova N. A. Malkova A. I. Nilov S. A. Sivertseva N. N. Spirin N. A. Totolyan F. A. Khabirov M. V. Shumilina |
| author_facet | K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. V. Davydovskaya M. N. Zakharova N. A. Malkova A. I. Nilov S. A. Sivertseva N. N. Spirin N. A. Totolyan F. A. Khabirov M. V. Shumilina |
| author_sort | K. Z. Bakhtiyarova |
| collection | DOAJ |
| description | Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs. A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS. The paper mentions the groups of patients in whom the drug, an examination before starting a therapy cycle, routes of administration, and dose, and a monitoring scheme during and after treatment cycles are indicated. This drug acts on the principle of selective immunoreconstitution and may occupy an important place in the treatment of HAMS. |
| format | Article |
| id | doaj-art-c217e7ea7284465eb0e7a0d9c87eea84 |
| institution | OA Journals |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| publishDate | 2020-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj-art-c217e7ea7284465eb0e7a0d9c87eea842025-08-20T02:16:18ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422020-06-01123939910.14412/2074-2711-2020-3-93-99991Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosisK. Z. Bakhtiyarova0A. N. Boyko1Ya. V. Vlasov2Z. A. Goncharova3M. V. Davydovskaya4M. N. Zakharova5N. A. Malkova6A. I. Nilov7S. A. Sivertseva8N. N. Spirin9N. A. Totolyan10F. A. Khabirov11M. V. Shumilina12G.G. Kuvatov Republican Clinical Hospital, Republican Center for Multiple Sclerosis; Bashkir State Medical University, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for the Brain and Neurotechnologies, Federal Biomedical AgencySamara State Medical University, Ministry of Health of RussiaRostov State Medical University, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Research and Practical Center for Clinical and Economic Analysis, Ministry of Health of the Moscow RegionResearch Center of NeurologyRegional Center for Multiple Sclerosis, State Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University, Ministry of Health of RussiaV.D. Seredavin Samara Regional Clinical HospitalAO «Neftyanik» Primary Healthcare Unit, Tyumen Regional Center for Multiple SclerosisYaroslavl State Medical University, Ministry of Health of RussiaAcad. I.P. Pavlov First Saint Petersburg State Medical UniversityKazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Republican Clinical Neurological CenterCity Clinical Hospital Thirty-One, City Center for Multiple SclerosisCurrently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs. A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS. The paper mentions the groups of patients in whom the drug, an examination before starting a therapy cycle, routes of administration, and dose, and a monitoring scheme during and after treatment cycles are indicated. This drug acts on the principle of selective immunoreconstitution and may occupy an important place in the treatment of HAMS.https://nnp.ima-press.net/nnp/article/view/1359highly active multiple sclerosisimmunoreconstitution therapycladribine tabletspregnancy and childbirth in multiple sclerosis |
| spellingShingle | K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. V. Davydovskaya M. N. Zakharova N. A. Malkova A. I. Nilov S. A. Sivertseva N. N. Spirin N. A. Totolyan F. A. Khabirov M. V. Shumilina Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis Неврология, нейропсихиатрия, психосоматика highly active multiple sclerosis immunoreconstitution therapy cladribine tablets pregnancy and childbirth in multiple sclerosis |
| title | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| title_full | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| title_fullStr | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| title_full_unstemmed | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| title_short | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| title_sort | recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis |
| topic | highly active multiple sclerosis immunoreconstitution therapy cladribine tablets pregnancy and childbirth in multiple sclerosis |
| url | https://nnp.ima-press.net/nnp/article/view/1359 |
| work_keys_str_mv | AT kzbakhtiyarova recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT anboyko recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT yavvlasov recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT zagoncharova recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT mvdavydovskaya recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT mnzakharova recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT namalkova recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT ainilov recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT sasivertseva recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT nnspirin recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT natotolyan recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT fakhabirov recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis AT mvshumilina recommendationsfortheuseofcladribinetabletsforthepathogenetictreatmentofpatientswithhighlyactivemultiplesclerosis |